Pre-order Enquiry
Request Free Sample
Global Schizophrenia Therapeutics Market Size, Status and Forecast 2019-2025
SKU ID : QYR-14440470 | Publishing Date : 11-Jul-2019 | No. of pages : 92
Request Sample
Request Customization
Check Discounts
Schizophrenia therapeutics are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.
The second-generation antipsychotic drugs segment accounted for the majority market shares because these drugs involve less side effects in comparison to their predecessors. The second-generation antipsychotic drugs are also called as atypical antipsychotic drugs. The increased efficacy and reduced side effects of these drugs improves the negative symptoms, decreases extrapyramidal side-effects (EPSE), and normalizes the level of prolactin. The improvement in negative and cognitive symptoms and the reduction in occurrences of EPSE is attributed to their antagonizing action on serotonin or 5-HT2A receptors. This in turn, will boost the segment’s growth throughout the estimated period.
In 2018, the global Schizophrenia Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Schizophrenia Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Schizophrenia Therapeutics development in United States, Europe and China.
The key players covered in this study
AstraZeneca
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Alkermes
AbbVie
Amgen
Bristol-Myers Squibb
Market segment by Type, the product can be split into
First-Generation Antipsychotic Drugs
Second-Generation Antipsychotic Drugs
Third-Generation Antipsychotic Drugs
Market segment by Application, split into
Hospitals
Clinics
Other
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Schizophrenia Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Schizophrenia Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Schizophrenia Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
The second-generation antipsychotic drugs segment accounted for the majority market shares because these drugs involve less side effects in comparison to their predecessors. The second-generation antipsychotic drugs are also called as atypical antipsychotic drugs. The increased efficacy and reduced side effects of these drugs improves the negative symptoms, decreases extrapyramidal side-effects (EPSE), and normalizes the level of prolactin. The improvement in negative and cognitive symptoms and the reduction in occurrences of EPSE is attributed to their antagonizing action on serotonin or 5-HT2A receptors. This in turn, will boost the segment’s growth throughout the estimated period.
In 2018, the global Schizophrenia Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Schizophrenia Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Schizophrenia Therapeutics development in United States, Europe and China.
The key players covered in this study
AstraZeneca
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Alkermes
AbbVie
Amgen
Bristol-Myers Squibb
Market segment by Type, the product can be split into
First-Generation Antipsychotic Drugs
Second-Generation Antipsychotic Drugs
Third-Generation Antipsychotic Drugs
Market segment by Application, split into
Hospitals
Clinics
Other
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Schizophrenia Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Schizophrenia Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Schizophrenia Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
